A comparison of methods for data-driven cancer outlier discovery, and an application scheme to semisupervised predictive biomarker discovery

Cancer Informatics

Volumn 10, Issue , 2011, Pages 109-120

  Karrila, Seppo ^a   Lee, Julian Hock Ean ^a   Tucker Kellogg, Greg ^a,b  

^a Eli Lilly Singapore Pte Ltd   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Biomarkers; Cancer; Outliers; Semisupervised; Translational

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 14; FIBRINOGEN; OSTEOPONTIN; PYRROLINE 5 CARBOXYLATE REDUCTASE; TRANSCRIPTION FACTOR MASH1;

ALGORITHM; ARTICLE; CANCER OUTLIER PROFILE ANALYSIS; CANCER RESEARCH; CELL LINE; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; LUNG NON SMALL CELL CANCER; NORMAL DISTRIBUTION; PROGNOSIS; SAMPLE; STATISTICAL ANALYSIS; STUDENT T TEST; TECHNOLOGY; TRANSLATIONAL RESEARCH; WORKFLOW;

EID: 79957852496     PISSN: 11769351     EISSN: 11769351     Source Type: Journal    
DOI: 10.4137/CIN.S6868     Document Type: Article

References (22)

1. Tucker-Kellogg G, Aggarwal A, Blanchard K, Gaynor R. Systems Biology in drug discovery: using predictive biomedicine to guide development choices for novel agents in cancer, in systems biolomedicine: concepts and Perspectives. Liu E, Lauffenburger D, editors. Academic Press; 2009.
2. MacDonald J, Ghosh D. COPA-cancer outlier profile analysis. Bioinformatics. 2006;22(23):2950-1.
3. Ertel A. Bimodal gene expression and biomarker discovery. Cancer Informatics. 2010;9:11-4.
4. Wang J, Wen S, Symmans W, Pusztai L, Coombes K. The bimodality index: a criterion for discovering and ranking bimodal signatures form cancer gene expression profiling data. Cancer Informatics. 2009;7:199-216.
5. Shiraishi T, Matsuyama S, Kitano H. Large-scale analysis of network bistability for human cancers. PLOS Comp Biol. 2010;6(7):e1000851.
6. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. PNAS. 2007:13086-91.
7. Tsuji K, Kawauchi S, Saito S, Furuya T, Ikemoto K, Nakao M, et al. Breast cancer cell lines carry cell line -specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues. BMC Cancer. 2010;10:15.
8. Bhattacharjee ARW. Classification of human lung carcinomas by Mrna expression profiling reveals distinct adenocarcinoma subclasses. PNAS. 2001:13790-5.
9. Lian H. MOST: detecting cancer differential gene expression. Biostatistics. 2008;9(3):411-8.
10. Wang Y, Rekaya R. LSOSS: detection of cancer outlier differential gene expression. Biomarker Insights. 2010;5:69-78.
11. Wu B. Cancer outlier differential gene expression detection. Biostatistics. 2007;8(3):566-75.
12. Tibshirani R, Hastie T. Outlier sums for differential gene expression analysis. Biostatistics. 2007;8(1):2-8.
13. Rapa I, Ceppi P, Bollito E, Rosas R, Cappia S, Bacillo E, et al. Human ASH1 expression in prostate cancer with neuroendocrine differentiation. Mod Pathol. 2008;21(6):700-7.
14. Somasundaram K, Reddy S, Vinnakota K, Britto R, Subbarayan M, Nambiar S, et al. Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Oncogene. 2005;27(47):7073-83.
15. Hemphill R. Hypercalcemia. Sep 1 2010. Retrieved Nov 24 2010, from Emedicine: http://emedicine.medscape.com/article/766373-overview.
16. Balanathan P, Williams E, Wang H, Pedersen J, Horvath L, Achen M, et al. Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer. Br J Cancer. 2009;100(11):1784-93.
17. Lappöhn R, Burger H, Bouma J. Inhibin as a marker for granulosa-cell tumors. N Engl J Med. 1989;321(12):790-3.
18. Pinese M, Scarlett C, Kench J, Colvin E, Segara D, Henshall S, et al. Messina: a novel analysis tool to identify biologically relevant molecules in disease. PLOS One. 2009;4(4):e5337.
19. Stephens M. Tests based on EDF statistcs. In: D'Agostino R, Stephens M. Goodness of Fit Techniques. New York: Marcel Dekker; 1986.
20. Tomlins S, Rhodes D, Perner S, Dhanasekaran S, Mehra R, Sun X, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644-8.
21. Wang Y, Zhang D, Zheng W, Luo J, Bai Y, Lu Z. Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer. 2008;112(6):1325-36.
22. Welt C, Sidis Y, Keutmann H, Schneyer A. Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp. Biol Med. 2002;227(9):724-52.